Highlights

  • Lotus Resources (ASX:LOT) shares traded at AUD 0.24, down 7.69% at the time of writing on 2 September 2026.
  • Uranium processing and acid production resumed at the Kayelekera mine in August 2026 after an operational interruption.
  • The company continues to work towards steady-state production at its restarted Malawi uranium operation.
  • Investors are monitoring production ramp-up, acid Supply security, funding and uranium sales execution.

The Australian Equity market was trading lower, with the S&P/ASX 200 (ASX:XJO) at 8,969.00 points, down 1.08% today, while the S&P/ASX 300 (ASX:XKO) was trading at 8,898.40 points, down 1.09% today. In contrast, the S&P/ASX 200 Energy (ASX:XEJ) was trading at 11,196.80 points, up 0.46% today.

Against this market backdrop, Lotus Resources Limited (ASX:LOT) traded at AUD 0.24, down 7.69% at the time of writing on 2 September 2026. The decline marks a notable daily move, although short-term price action alone does not establish a change in the underlying value or operating outlook of the company.

For Lotus, investor attention is particularly centred on its transition from uranium project developer to producer and the operational performance of the restarted Kayelekera Uranium Mine in Malawi.

African Uranium Portfolio

Lotus Resources (ASX:LOT) is an Africa-focused uranium company with a portfolio comprising the producing Kayelekera mine in Malawi and the Letlhakane uranium project in Botswana.

The company states that its portfolio contains a combined global Mineral Resource of around 165 million pounds of U3O8. Kayelekera accounts for a Mineral Resource of approximately 51.5 million pounds of U3O8 at 475 ppm, while Letlhakane represents a much larger undeveloped uranium resource in Botswana.

Kayelekera has become the company’s immediate operational priority. The mine historically operated before being placed on care and maintenance and was subsequently restarted by Lotus. Uranium production recommenced in August 2025, placing the company among a relatively limited group of listed uranium businesses that have moved from development into production.

The longer-term Investment case therefore depends not only on uranium resource scale but also on Lotus’ ability to establish consistent production, manage operating costs and deliver product into customer contracts.

August Restart

A significant operational update emerged in August 2026 when Lotus reported the resumption of both acid production and uranium processing at Kayelekera.

Processing had been suspended in June after disruption to third-party sulphuric acid supply coincided with a setback during commissioning of the mine’s sulphuric acid plant. The issue involved partial failure of refractory bricks within the sulphur furnace.

By August, interim furnace repair works had been completed and acid inventories had been replenished, allowing both the acid plant and uranium processing plant to restart.

The development was important because reliable sulphuric acid availability is a key input for Kayelekera’s processing operations. Lotus indicated that sufficient sulphur inventory was available on site, together with supply visibility for the remainder of calendar 2026.

Management also highlighted the strategic role of the acid plant in improving security of reagent supply and reducing reliance on externally sourced acid.

During the production interruption, the company continued plant optimisation and maintenance work designed to support the operation as it progresses towards steady-state production.

Lotus has previously targeted steady-state output of approximately 200,000 pounds of U3O8 per month, equivalent to around 2.4 million pounds per annum. Achieving sustained production near that level remains one of the key operational milestones for investors to watch.

Funding Reset

Operational execution has not been the only major issue on the market’s radar.

During July 2026, Lotus implemented a broader funding and balance-sheet package intended to support the continued ramp-up at Kayelekera and provide additional financial flexibility.

The company completed the institutional component of a fully underwritten pro-rata entitlement offer, raising approximately AUD 34.2 million from institutional investors.

The broader financing structure also incorporated a proposed AUD 35 million senior unsecured convertible note and a USD 30 million inventory-backed prepayment facility.

For a company moving a mine through the ramp-up phase, access to sufficient Working Capital can be particularly important. Production restarts can involve periods of elevated expenditure before operations achieve consistent throughput and cash generation.

Lotus’ funding initiatives therefore form an important part of the investment picture alongside physical production performance.

Investors are likely to monitor how effectively the company deploys this capital as Kayelekera moves through optimisation, inventory build-up and uranium shipment stages.

Production Watch

Uranium producers are exposed to a different set of considerations than earlier-stage uranium explorers.

Once production begins, investor focus increasingly shifts towards plant availability, recovery rates, reagent consumption, operating costs, shipment schedules and contractual sales commitments.

For Lotus Resources, the reliability of Kayelekera’s processing infrastructure remains particularly important. The recent acid supply constraints demonstrated how operational inputs can affect the pace of a production ramp-up even when the underlying resource and processing infrastructure are already established.

At the same time, successfully operating the company-owned acid plant could reduce this exposure over time by improving supply security and lowering reagent costs.

The uranium market backdrop also remains relevant. Nuclear power continues to feature in global energy security and decarbonisation discussions, supporting long-term interest in uranium supply. However, uranium prices and contracting conditions can fluctuate, meaning producers still need to maintain disciplined operating and financing strategies.

Letlhakane provides Lotus with a longer-duration growth option beyond Kayelekera. The Botswana asset is one of the larger undeveloped uranium projects within the company’s portfolio, although near-term investor attention is likely to remain concentrated on proving sustainable operations in Malawi.

Investor Attention

The 7.69% decline in Lotus Resources shares at the time of writing on 2 September 2026 is sizeable for a single session, but the movement should be viewed separately from the company’s operational announcements unless a direct connection is established.

Daily trading can reflect numerous factors, including investor positioning, broader uranium-sector sentiment, liquidity, portfolio Rebalancing and changing risk appetite.

For Lotus Resources (ASX:LOT), the more fundamental indicators remain operational.

Investors are likely to watch whether Kayelekera can maintain uninterrupted processing, increase uranium output and transition towards steady-state performance. They will also assess the effectiveness of the acid plant, funding requirements, uranium shipment progress and the company’s ability to meet contractual obligations.

The balance between production improvement and capital requirements may remain especially important during the ramp-up period.

Final Takeaway

Lotus Resources (ASX:LOT) is navigating an important phase in its evolution as a uranium producer. Its share price traded at AUD 0.24, down 7.69% at the time of writing on 2 September 2026, while operational attention remains focused on the Kayelekera mine.

The August 2026 restart of acid production and uranium processing marked an important step after the June interruption. With processing back online, the company’s next challenge is demonstrating sustainable output and progressing towards its targeted steady-state operating level.

Short-term share price weakness does not by itself determine the company’s longer-term fundamentals. For Lotus, production consistency, funding discipline, reagent security, uranium deliveries and execution at Kayelekera are likely to remain the primary areas under investor scrutiny.